Charcoal
| 證據等級: L5 | 預測適應症: 0 個 |
目錄
Charcoal: Evidence Pack Incomplete — Repurposing Evaluation Pending
One-Sentence Summary
Charcoal is a pharmaceutical-grade adsorbent agent used in emergency medicine for acute poisoning and drug overdose management. This Evidence Pack contains no TxGNN-generated repurposing predictions and is missing critical data fields including DrugBank linkage, mechanism of action, and UK marketing authorisation records. A full repurposing evaluation cannot be completed in the current state; this report documents what is available and outlines the steps required to proceed.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not available in this Evidence Pack |
| Predicted New Indication | No predictions generated |
| TxGNN Prediction Score | Not available |
| Evidence Level | Below L5 — no predictions or supporting studies present |
| UK Market Status | Not currently authorised (per Evidence Pack) |
| Number of Marketing Authorisations | 0 |
| Recommended Decision | Hold |
Why This Evaluation Cannot Yet Be Completed
No repurposing predictions have been generated by the TxGNN model for this candidate, and no DrugBank ID has been linked. Without a prediction target, it is not possible to assess mechanistic plausibility or identify a new indication to evaluate.
Activated charcoal is well established in clinical practice as a broad-spectrum gastrointestinal adsorbent, primarily deployed in emergency toxicology settings. Its adsorptive properties operate across a wide range of compounds, which in principle could offer mechanistic relevance to multiple therapeutic areas. However, no formal repurposing hypothesis can be assessed until the TxGNN pipeline has been run successfully against a confirmed drug identifier.
The DrugBank query on 27 March 2026 returned one result (status: success), suggesting the compound is identifiable, but the DrugBank ID was not propagated into the Evidence Pack. This is likely the root cause of the downstream prediction failure.
Clinical Trial Evidence
Currently no related clinical trials registered for this candidate’s predicted indications.
Literature Evidence
Currently no related literature available for this candidate’s predicted indications.
UK Market Information
No marketing authorisations are recorded for Charcoal in this Evidence Pack. This is likely a data collection artefact: activated charcoal formulations are commercially available in the United Kingdom under several brand names (e.g., CharcoAid, Actidose-Aqua). The automated pull may have failed to match the queried drug name to MHRA product records.
Manual verification against the MHRA product licence database using the INN “activated charcoal” and known brand name variants is strongly recommended before concluding that no UK authorisation exists.
Safety Considerations
Please refer to the SmPC and BNF for safety information. Report suspected adverse reactions via the Yellow Card Scheme.
Conclusion and Next Steps
Decision: Hold
Rationale: The Evidence Pack is structurally incomplete — no TxGNN prediction output is present, the DrugBank identifier is missing, and all safety and regulatory fields are unpopulated. No meaningful repurposing evaluation can be conducted until the pipeline is re-run with correct inputs.
To proceed, the following is needed:
- Resolve the DrugBank ID gap: The DrugBank query returned a successful hit; retrieve and populate the DrugBank ID, MOA, drug categories, and toxicity data from that result
- Re-run the TxGNN prediction pipeline using the confirmed DrugBank ID to generate repurposing candidates and prediction scores
- Verify UK marketing authorisations manually via the MHRA products database searching by “activated charcoal” and known brand names, to correct the apparent zero-licence result
- Retrieve SmPC safety data including warnings, contraindications, and drug interactions from the MHRA-approved SmPC
- Re-run evidence collection (ClinicalTrials.gov, PubMed, ICTRP) once a top-ranked predicted indication is available
- Re-issue this report once a complete Evidence Pack (v5 or later) is available
⚠️ Disclaimer: This report is for research purposes only and does not constitute medical advice. Any drug repurposing candidates identified require clinical validation before therapeutic application.
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.